[Advances in the treatment of juvenile myelomonocytic leukemia].
作者信息
Cai Yu-Li, Zhang Jing-Liao, Zhu Xiao-Fan
机构信息
Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China.
出版信息
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Nov;20(11):958-963. doi: 10.7499/j.issn.1008-8830.2018.11.016.
Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare chronic myeloid leukemia in children and has the features of both myelodysplastic syndrome and myeloproliferative neoplasm. It is highly malignant and has a poor treatment outcome. Children with JMML have a poor response to conventional chemotherapy. At present, hematopoietic stem cell transplantation is the only possible cure for this disease. In recent years, significant progress has been made in targeted therapy for mutant genes in the Ras signaling pathway and demethylation treatment of aberrant methylation of polygenic CpG islands. This article reviews the treatment and efficacy evaluation of JMML.
摘要
相似文献
1
[Advances in the treatment of juvenile myelomonocytic leukemia].
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Nov;20(11):958-963. doi: 10.7499/j.issn.1008-8830.2018.11.016.
2
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Semin Cancer Biol. 2018 Aug;51:68-79. doi: 10.1016/j.semcancer.2017.10.011. Epub 2017 Nov 9.
3
Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
Pediatr Blood Cancer. 2022 Nov;69(11):e29930. doi: 10.1002/pbc.29930. Epub 2022 Sep 12.
4
Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Blood. 2019 Mar 7;133(10):1060-1070. doi: 10.1182/blood-2018-11-844688. Epub 2019 Jan 22.
5
Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
Blood. 2014 Oct 16;124(16):2487-97. doi: 10.1182/blood-2014-03-300319. Epub 2014 Aug 27.
6
Juvenile myelomonocytic leukemia.
Semin Diagn Pathol. 2011 Nov;28(4):298-303. doi: 10.1053/j.semdp.2011.08.007.
7
Juvenile myelomonocytic leukemia.
Pediatr Clin North Am. 2015 Feb;62(1):95-106. doi: 10.1016/j.pcl.2014.09.003.
8
Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Br J Haematol. 2008 May;141(5):567-75. doi: 10.1111/j.1365-2141.2008.07104.x. Epub 2008 Apr 13.
9
Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
Br J Haematol. 2008 Mar;140(6):610-24. doi: 10.1111/j.1365-2141.2007.06958.x.
10
The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Virchows Arch. 2023 Jan;482(1):113-130. doi: 10.1007/s00428-022-03447-9. Epub 2022 Nov 29.
本文引用的文献
1
Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Expert Rev Hematol. 2018 Feb;11(2):129-143. doi: 10.1080/17474086.2018.1421937. Epub 2018 Jan 3.
2
Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
Nat Commun. 2017 Dec 19;8(1):2127. doi: 10.1038/s41467-017-02178-9.
3
Clinical outcomes of unrelated cord blood transplantation in children with malignant and non-malignant diseases: Multicenter experience in China.
Pediatr Transplant. 2018 Feb;22(1). doi: 10.1111/petr.13090. Epub 2017 Dec 14.
4
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Semin Cancer Biol. 2018 Aug;51:68-79. doi: 10.1016/j.semcancer.2017.10.011. Epub 2017 Nov 9.
5
Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report.
J Investig Med High Impact Case Rep. 2017 Sep 8;5(3):2324709617728528. doi: 10.1177/2324709617728528. eCollection 2017 Jul-Sep.
6
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.
7
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Leukemia. 2017 Jun;31(6):1415-1422. doi: 10.1038/leu.2016.326. Epub 2016 Nov 14.
8
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Nature. 2016 Nov 10;539(7628):304-308. doi: 10.1038/nature20131. Epub 2016 Oct 26.
9
MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
Oncotarget. 2016 Aug 23;7(34):55395-55408. doi: 10.18632/oncotarget.10577.
10
Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.
Bone Marrow Transplant. 2016 Sep;51(9):1211-6. doi: 10.1038/bmt.2016.101. Epub 2016 Apr 18.
Zotero 插件